Core Points - The document outlines the rules and regulations governing the board of directors of Shandong Weiming Pharmaceutical Biological Co., Ltd, ensuring independent and effective decision-making [1][3][36] Group 1: Board Composition and Responsibilities - The board consists of 5 to 11 directors, including one employee representative, with a term of three years [1][2] - The board is responsible for convening shareholder meetings, executing resolutions, and making decisions on operational plans and investment proposals [2][3] - The board has the authority to approve significant transactions, including asset purchases, sales, and external investments, with specific thresholds for approval [4][5] Group 2: Meeting Procedures - Regular board meetings must be held at least twice a year, while temporary meetings can be called under specific circumstances [11][12] - A quorum requires the presence of more than half of the directors, and decisions are made through a voting process [16][19] - Meeting records must be maintained, detailing attendees, agenda items, and voting outcomes [27][28] Group 3: Committees and Oversight - The board establishes specialized committees, including a strategic decision-making committee, audit committee, and remuneration committee, to enhance governance [3][4] - Independent directors must constitute a majority in certain committees, ensuring unbiased oversight [3][4] - The board is tasked with monitoring the implementation of its resolutions and ensuring compliance with legal and regulatory requirements [30][31]

General Overview - The document outlines the working rules of the Audit Committee of Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to enhance the decision-making capacity of the board and ensure effective supervision of the management [1][2]. Composition of the Audit Committee - The Audit Committee consists of three directors, including two independent directors, with an accounting professional serving as the chairperson [2]. - The committee members are nominated by the chairman or a majority of independent directors and elected by the board [2]. - The term of the Audit Committee aligns with that of the board, and members can be re-elected [2]. Responsibilities and Authority - The main responsibilities of the Audit Committee include supervising external and internal audits, reviewing financial reports, and assessing internal controls [4][5]. - The committee must approve certain actions, such as the disclosure of financial reports and the hiring or firing of external auditors, before submission to the board [10][11]. - The committee is tasked with guiding and supervising the internal audit department and ensuring compliance with laws and regulations [12]. Meeting Procedures - The Audit Committee is required to hold at least one regular meeting each quarter, with provisions for special meetings as needed [22][23]. - Meeting notifications must include the date, location, agenda, and other relevant details [24]. - A quorum for meetings requires the presence of at least two-thirds of the committee members, and decisions are made by a majority vote [26][27]. Documentation and Reporting - Meeting minutes must be recorded, detailing attendance, agenda items, and voting results, and these records are to be maintained for a minimum of ten years [33][36]. - The committee is responsible for reporting its activities and any significant issues to the board, ensuring transparency and accountability [20][21].

Core Viewpoint - The document outlines the fundraising management system of Shandong Weiming Biological Pharmaceutical Co., Ltd, emphasizing the proper storage, usage, and management of raised funds to enhance efficiency and protect investors' rights [1][2]. Group 1: Fundraising Management Principles - The company must establish a detailed plan for the use of raised funds, ensuring transparency and compliance with national laws and regulations [2][4]. - The board of directors is responsible for the effective implementation of the fundraising management system [1][2]. - Funds raised must be stored in a dedicated account and cannot be used for non-designated purposes [7][8]. Group 2: Fund Usage Regulations - Raised funds should be used strictly for the purposes disclosed in the prospectus or other public documents, and any changes must be approved by the shareholders [9][11]. - The company is prohibited from using raised funds for high-risk investments or providing financial assistance to others [11][12]. - Any changes in the investment projects must undergo a feasibility analysis and be disclosed promptly [14][15]. Group 3: Oversight and Reporting - The company must maintain detailed records of the usage of raised funds and undergo regular audits to ensure compliance [33][34]. - The board must report on the status of fundraising and usage at least semi-annually, including any discrepancies in investment progress [15][16]. - Independent financial advisors or sponsors are required to conduct regular checks and report any irregularities [17][18].

Core Points - The article outlines the investor relations management system of Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to enhance communication with investors and improve corporate governance [1][2][3] - The management system emphasizes compliance, proactivity, equality, and integrity in investor relations activities [3][4] - The company aims to establish a stable investor base, increase transparency, and improve overall corporate value through effective communication and information disclosure [2][4] Summary by Sections General Principles - The investor relations management system is designed to strengthen communication between the company and its investors, enhancing understanding and recognition [1][2] - The objectives include improving information disclosure, building a quality investor base, fostering a respectful corporate culture, and enhancing governance [2][3] Management Principles - Compliance with laws and regulations is fundamental to the investor relations management activities [3][4] - The company should proactively engage with investors, addressing their suggestions and concerns in a timely manner [3][4] - Equal treatment of all investors, especially minority shareholders, is a key principle [3][4] Communication Content and Methods - Communication with investors will cover various topics, including company strategy, legal disclosures, operational information, and social responsibility [5][6] - Multiple channels such as the company website, social media, and direct communication methods will be utilized to facilitate investor engagement [5][6] - The company will maintain a dedicated investor relations section on its website to address inquiries and complaints [5][6] Responsibilities and Activities - The company will organize investor relations activities, handle inquiries, and maintain communication channels [8][9] - Regular training for management and staff on investor relations practices will be conducted to enhance communication skills [11][12] - The company will document investor relations activities and ensure compliance with disclosure regulations [11][12] Investor Meetings and Events - Investor meetings, including performance briefings and Q&A sessions, will be held to address investor concerns and provide updates [7][8] - The company will ensure that meetings are accessible and provide opportunities for all investors to participate [8][9] - Special attention will be given to avoid disclosing any undisclosed material information during these interactions [10][12]

Core Points - The document outlines the internal reporting system for significant information at Shandong Weiming Bio-Pharmaceutical Co., Ltd, ensuring timely and accurate disclosure of information that may impact stock prices and investor rights [1][2][3] Group 1: Internal Reporting Obligations - The system mandates that individuals with reporting obligations must promptly report significant information to the chairman and board secretary [2][3] - Reporting obligations include directors, senior management, department heads, and significant shareholders [2][3] - The board secretary is responsible for organizing and coordinating information disclosure [2][3] Group 2: Definition of Significant Information - Significant information includes major meetings, transactions, litigation, changes, and risks that could affect stock prices [3][4] - Specific thresholds for reporting transactions are established, such as asset transactions exceeding 10% of total assets or significant revenue impacts [4][5] Group 3: Reporting Procedures - The reporting process requires immediate notification of significant events, with both verbal and written communication to the board secretary [29][30] - The board secretary must assess whether the information requires public disclosure and report to the board accordingly [30][31] Group 4: Responsibilities and Accountability - The board of directors oversees the internal reporting and external disclosure processes [32][33] - Individuals failing to meet reporting obligations may face disciplinary actions, including fines or termination [21][22] Group 5: Additional Reporting Requirements - The document specifies additional reporting for related party transactions, litigation, and significant operational changes [10][11][12] - Social responsibility incidents, such as environmental accidents, must also be reported [21]

Core Viewpoint - The document outlines the establishment and operational guidelines of the Compensation and Assessment Committee of Shandong Weiming Bio-Pharmaceutical Co., Ltd, aimed at enhancing the governance structure and management of compensation for directors and senior management [1][2]. Group 1: General Provisions - The Compensation and Assessment Committee is established to improve the assessment and compensation management system for directors and senior management, in accordance with relevant laws and regulations [1]. - The committee is responsible for formulating and reviewing compensation policies and assessment standards for directors and senior management [1][2]. Group 2: Composition of the Committee - The committee consists of three directors, including two independent directors [2]. - The chairman of the committee is an independent director, responsible for leading the committee's work [2]. Group 3: Responsibilities and Authority - The committee's main responsibilities include researching assessment standards for directors and senior management, reviewing compensation policies, and other matters authorized by the board [3]. - Compensation proposals for directors must be approved by the board and submitted for shareholder meeting approval, while senior management compensation requires board approval [3][4]. Group 4: Decision-Making Procedures - The committee has a working group to prepare for decision-making, providing necessary financial and performance data [4]. - The assessment process involves self-evaluation by directors and senior management, followed by performance evaluations conducted by the committee [4][5]. Group 5: Meeting Rules - The committee meets as needed, with a requirement for two-thirds of members to be present for decisions [5]. - Meeting decisions require a majority vote, and the committee can invite other relevant personnel to attend meetings for explanations [5][6]. Group 6: Confidentiality and Compliance - Members and attendees of the committee meetings are obligated to maintain confidentiality regarding undisclosed information [6]. - The committee's operations must comply with relevant laws, regulations, and the company's articles of association [7].

山东未名生物医药股份有限公司 董事会战略决策委员会工作细则 （经2025年7月30日召开的第六届董事会第四次会议审议通过） 第一章 总则 第六条 主任委员负责召集、主持委员会工作。主任委员不能履行职务或无 法履行职责的，由战略委员会委员选举一名委员代行主任委员职责。 第七条 战略委员会委员任期与董事会董事任期一致，委员任期届满，可以 连选连任。委员任期届满前，除非出现《公司法》《公司章程》或本细则规定的 不得任职之情形，不得被无故解除职务。期间如有委员不再担任公司董事职务， 自动失去委员资格。董事会根据本细则的规定增补新的委员。 第八条 战略委员会委员可以在任期届满以前提出辞职，委员辞职应当向董 事会提交书面辞职报告，且在补选出的委员就任前，原委员仍应当依照本议事规 则细则的规定，履行相关职责。 第一条 为了适应山东未名生物医药股份有限公司（下称公司）战略发展需 要，提升公司核心竞争力，健全战略规划的决策程序，根据《中华人民共和国 公司法》（以下简称《公司法》）、《上市公司治理准则》和《深圳证券交易 所上市公司自律监管指引第1号—主板上市公司规范运作》等法律、行政法规、 部门规章、规范性文件及《山东未名生物医 ...

山东未名生物医药股份有限公司董事会 提名委员会工作细则 （经2025年7月30日召开的第六届董事会第四次会议审议通过） 第一章 总则 第一条 为规范山东未名生物医药股份有限公司（下称公司）董事及高级管 理人员的选聘，优化董事会成员组成，完善公司治理结构，根据《中华人民共 和国公司法》（以下简称《公司法》）、《上市公司治理准则》和《深圳证券 交易所上市公司自律监管指引第1号—主板上市公司规范运作》等法律、行政法 规、部门规章、规范性文件及《山东未名生物医药股份有限公司章程》（以下 简称《公司章程》）的规定，结合公司实际情况，设立董事会提名委员会（以 下简称提名委员会），并制定本细则。 第二条 提名委员会是董事会设立的专门工作机构，对董事会负责，依照 《公司章程》和董事会的授权履行职责。提名委员会主要负责对公司董事和高 级管理人员的人选、选择标准和程序进行选择并提出建议。 第七条 提名委员会任期与董事会任期一致，委员任期届满，连选可以连 任。 委员任期届满前，除非出现《公司法》《公司章程》或本细则规定的不得 任职之情形，不得被无故解除职务。期间如有委员不再担任公司董事职务，自 动失去委员资格，董事会根据本细则的规 ...

及其变动管理制度 （经 2025 年 7 月 30 日召开的第六届董事会第四次会议审议通过） 董事和高级管理人员所持公司股份 第一章 总则 山东未名生物医药股份有限公司 第一条 为加强对山东未名生物医药股份有限公司（以下简称公司或本公司） 董事和高级管理人员所持本公司股份及其变动的管理，进一步明确办理程序，根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》（以下简称《证券法》）、《上市公司董事和高级管理人员所持本公司股份 及其变动管理规则》、《上市公司股东减持股份管理暂行办法》、《深圳证券交 易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》 （以下简称《监管指引第 18 号》）、《深圳证券交易所股票上市规则》（以下 简称《股票上市规则》）、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》、《深圳证券交易所上市公司自律监管指引第 10 号— —股份变动管理》等法律、行政法规、部门规章、规范性文件以及《山东未名生 物医药股份有限公司章程》（以下简称《公司章程》）的有关规定，结合公司实 际情况，制定本制度。 第二条 本制度适用于公司董 ...

山东未名医药生物股份有限公司 总经理、联席总经理工作细则 第一章 总则 第一条 为进一步完善山东未名医药生物股份有限公司（以下简称公司）治 理结构，规范公司总经理、联席总经理的工作，依照《中华人民共和国公司法》 （以下简称《公司法》）、《深圳证券交易所股票上市规则》、《上市公司治理 准则》等法律、行政法规、部门规章、规范性文件以及《山东未名医药生物股份 有限公司章程》（以下简称《公司章程》）有关规定，特制定本细则。 第二条 公司依法设置总经理、联席总经理。总经理、联席总经理主持公司 日常生产经营和管理工作，组织实施董事会决议，对董事会负责。 第二章 总经理、联席总经理的任职资格与任免程序 第三条 总经理、联席总经理任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营 管理能力； （二）具有调动员工积极性的领导能力。建立合理的组织机构、协调各种内 外关系和统揽全局的能力； （三）诚信勤勉，廉洁奉公，民主公道。 第四条 有下列情形之一者，不得担任公司总经理、联席总经理： （一）无民事行为能力或者限制民事行为能力者； （二）因贪污、贿赂、侵占财产、挪用财产罪或者破坏社会主义市场 ...